GlassScriptPhysician profile
Jordin Swanson
NPI 1861148645
$6,003.55
in general payments reported to CMS, 2019-2025
27 companies · $1,734 in 2025
The $1,734 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,272 · 2023: $1,556 · 2024: $1,442 · 2025: $1,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,707 · Education: $24.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,707.36 |
| Education | $24.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,588.71 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $995.99 | 2022-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $450.79 | 2022-2025 | |
| Ardelyx, INC. | $342.20 | 2023-2025 | Ibsrela |
| Celgene Corporation | $330.87 | 2022-2023 | Zeposia |
| Janssen Biotech, INC. | $315.76 | 2022-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $256.21 | 2022-2024 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $245.86 | 2022-2025 | Entyvio, Gattex |
| Daiichi Sankyo INC. | $225.61 | 2022-2024 | Injectafer |
| Celltrion USA INC. | $200.96 | 2024-2025 | Zymfentra, Vegzelma |
| Regeneron Healthcare Solutions, INC. | $190.49 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $161.87 | 2024-2025 | Zepbound, Omvoh |
| Intercept Pharmaceuticals, INC. | $118.08 | 2022-2024 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $96.42 | 2022 | |
| Merck Sharp & Dohme LLC | $90.54 | 2022-2024 | Dificid |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $53.23 | 2023 | |
| Madrigal Pharmaceuticals | $48.13 | 2024 | Resmetirom |
| Ferring Pharmaceuticals INC. | $47.13 | 2023-2024 | Rebyota |
| Mallinckrodt Hospital Products INC. | $44.98 | 2023-2024 | Terlivaz |
| Phathom Pharmaceuticals, INC. | $41.94 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $39.66 | 2022 | |
| Redhill Biopharma INC. | $31.93 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.22 | 2023 | Cyltezo |
| Aimmune Therapeutics, INC. | $18.02 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $17.13 | 2024 | Iqirvo |
| Braintree Laboratories, INC. | $16.19 | 2023 | Sutab |
| Sandoz INC. | $14.63 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordin Swanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.